Previous research has validated hematopoietic progenitor kinase 1 (HPK1) as a target in immune oncology, and pharmacological inhibition of HPK1 has been shown to enhance effector T-cell function and antitumor activity.
Hoth Therapeutics Inc. has reported promising results from sponsored preclinical research conducted at NC State University (NCSU) with HT-KIT, the company’s new molecular entity for the treatment of advance systemic mastocytosis. HT-KIT is an antisense oligonucleotide that targets the proto-oncogene c-Kit by inducing mRNA frame shifting.
Lipids are “very diverse, but also vastly understudied,” Anne Brunet told the audience at the recent meeting on Aging Research and Drug Discovery. Advances in the ability to predict protein structures have fueled a much better understanding of the human proteome and its estimated 20,000 members. The lipidome is much larger, numbering maybe 100,000 total. And what those lipids do remains much more fuzzy. “Very little is known about their function, and especially their function during aging,” Brunet said. Slowly, however, technological advances are enabling researchers to understand the roles of lipids as well.
Dewpoint Therapeutics Inc. and Chemify Ltd. have partnered to develop a suite of digitally discovered and automatically synthesized novel molecules on Chemify’s programmable chemistry platform against condensate targets of interest in Dewpoint’s oncology and neurodegeneration pipeline.
Geode Therapeutics Inc. and Xtalpi Inc. have jointly developed stimulator of interferon genes protein (STING; TMEM173) modulators reported to be useful for the treatment of cancer, infections and autoimmune disease.
Research at MUSC Foundation for Research Development has led to the identification of small molecules targeting the voltage-dependent anion channel (VDAC) NADH binding pocket.
Researchers from the University of Oxford and Oxstem Ltd. have discovered small-molecule candidates with the ability to induce differentiation of acute myeloid leukemia (AML) cells.
Pancreatic ductal adenocarcinoma (PDAC) is an exocrine pancreatic cancer with a poor prognosis and limited treatment options. There is a strong demand for new treatment strategies to overcome these challenges.
Riana Therapeutics GmbH, a spin-off from Vetmeduni Vienna founded this year, has entered into a collaborative agreement with the Lead Discovery Center GmbH (LDC) to support its efforts to discover and develop novel cancer therapeutics that disrupt oncogenic protein-protein interactions (PPIs).
Springboarding off the success of its AI-based imaging software for cancer detection, the deep learning-based artificial intelligence (AI) company Lunit Inc. has another AI software, called the Lunit Scope, up its sleeve for which it hopes to gain U.S. FDA approval by 2025.
RSS
